CRVS insider buying and SEC filings, explained
Corvus Pharmaceuticals, Inc. · CIK 1626971
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$334K
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 11, 2026 | Purchase (code P) | David Scott Moore (Director) bought 21,700 shares at $11.53 ($250K), reported as a purchase (code P). New position of 21,700 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 15, 2026 |
| May 18, 2026 | Purchase (code P) | Richard A. Md Miller (CEO and Director) bought 6,932 shares indirectly (by trust) at about $12.04 ($83K), reported as a purchase (code P). Holdings by trust up 1% to 1,195,035 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 20, 2026 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
2 insiders bought in 30 days
$334K in purchases since May 18, 2026 · Purchases traded May 18, 2026 to Jun 11, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Richard A. Md Miller (CEO) | $83K | May 18, 2026 | SEC filing |
| David Scott Moore (Director) | $250K | Jun 11, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CRVS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.